A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10501 Tablets After Single and Multiple Oral Doses in Healthy Subjects
Latest Information Update: 16 Apr 2024
At a glance
- Drugs HS 10501 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
- 16 Apr 2024 New trial record